Patents by Inventor Jiangong Shi

Jiangong Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12251413
    Abstract: The present disclosure provides use of an effective part extract of Monochasma savatieri in preparation of a drug for treating an inflammatory disease or a tumor. In the present disclosure, an effective part of Monochasma savatieri is separated and purified by various separation and purification methods (including solvent extraction, macroporous resin column chromatography, MCI column separation, and Sephadex LH-20 gel column separation) separately, to obtain the effective part extract of Monochasma savatieri. The effective part extract of Monochasma savatieri is capable of significantly inhibiting secretion of TNF-?, and significantly inhibiting proliferation of breast cancer cells and lung cancer cells, thereby effectively treating the inflammatory disease or the tumor. The present disclosure provides a favorable theoretical basis for finding a drug that can effectively treat the inflammatory disease or the tumor from the Monochasma savatieri, which is of great significance to development of novel drugs.
    Type: Grant
    Filed: September 5, 2022
    Date of Patent: March 18, 2025
    Assignees: HARBIN KANGLONG PHARMACEUTICAL CO., LTD, YICHUN BINGCHEN AGRICULTURAL TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Bin Mu, Jiangong Shi, Tiantai Zhang, Qinglan Guo, Weiquan Li
  • Publication number: 20230398168
    Abstract: The present disclosure provides use of an effective part extract of Monochasma savatieri in preparation of a drug for treating an inflammatory disease or a tumor. In the present disclosure, an effective part of Monochasma savatieri is separated and purified by various separation and purification methods (including solvent extraction, macroporous resin column chromatography, MCI column separation, and Sephadex LH-20 gel column separation) separately, to obtain the effective part extract of Monochasma savatieri. The effective part extract of Monochasma savatieri is capable of significantly inhibiting secretion of TNF-?, and significantly inhibiting proliferation of breast cancer cells and lung cancer cells, thereby effectively treating the inflammatory disease or the tumor. The present disclosure provides a favorable theoretical basis for finding a drug that can effectively treat the inflammatory disease or the tumor from the Monochasma savatieri, which is of great significance to development of novel drugs.
    Type: Application
    Filed: September 5, 2022
    Publication date: December 14, 2023
    Inventors: Bin Mu, Jiangong Shi, Tiantai Zhang, Qinglan Guo, Weiquan Li
  • Patent number: 10174033
    Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: January 8, 2019
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
  • Patent number: 9849145
    Abstract: Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed. The honeysuckle extract is used in combination with the antibiotics, the responsiveness of multi-drug resistant bacteria to antibiotics is improved, a clinical application prospect is presented, especially the current status of the refractory bacterial infection diseases caused by the pathogenic bacteria resistant to the antibiotics can be improved. Also provided is a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for prevention and/or treatment a diseases caused by bacteria.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: December 26, 2017
    Assignee: Hankang Biochemical & Pharmaceutical Co., Ltd
    Inventors: Tiejun Zhang, Jiangong Shi, Hong Meng, Fengnian Han, Xuwei Ma, Zhulan Li
  • Publication number: 20140193530
    Abstract: Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed. The honeysuckle extract is used in combination with the antibiotics, the responsiveness of multi-drug resistant bacteria to antibiotics is improved, a clinical application prospect is presented, especially the current status of the refractory bacterial infection diseases caused by the pathogenic bacteria resistant to the antibiotics can be improved. Also provided is a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for prevention and/or treatment a diseases caused by bacteria.
    Type: Application
    Filed: August 12, 2011
    Publication date: July 10, 2014
    Inventors: Tiejun Zhang, Jiangong Shi, Hong Meng, Fengnian Han, Xuwei Ma, Zhulan Li
  • Publication number: 20130045942
    Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
    Type: Application
    Filed: December 10, 2009
    Publication date: February 21, 2013
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
  • Patent number: 7557089
    Abstract: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by ?-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: July 7, 2009
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Science
    Inventors: Jianjun Zhang, Jiangong Shi, Yafang Wang, Dan Zhang, Mei Gao, Yongchun Yang, Shengyang Huang
  • Publication number: 20060281692
    Abstract: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by ?-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.
    Type: Application
    Filed: December 31, 2003
    Publication date: December 14, 2006
    Inventors: Jianjun Zhang, Jiangong Shi, Yafang Wang, Dan Zhang, Mei Gao, Yongchun Yang